Literature DB >> 11114720

Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.

M Krieg1, R Haas, H Brauch, T Acker, I Flamme, K H Plate.   

Abstract

Hypoxia induces transcription of a range of physiologically important genes including erythropoietin and vascular endothelial growth factor. The transcriptional activation is mediated by the hypoxia-inducible factor-1 (HIF-1), a heterodimeric member of the basic helix-loop-helix PAS family, composed of alpha and beta subunits. HIF-1alpha shares 48 per cent identity with the recently identified HIF-2alpha protein that is also stimulated by hypoxia. In a previous study of hemangioblastomas, the most frequent manifestation of hereditary von Hippel-Lindau disease (VHL), we found elevated levels of vascular endothelial growth factor and HIF-2alpha mRNA in stromal cells of the tumors. Mutations of the VHL tumor suppressor gene are associated with a variety of tumors such as renal clear cell carcinomas (RCC). In this study, we analysed the expression of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in a range of VHL wildtype and VHL deficient RCC cell lines. In the presence of functional VHL protein, HIF-1alpha mRNA levels are elevated, whereas HIF-2alpha mRNA expression is increased only in cells lacking a functional VHL gene product. On the protein levels, however, in VHL deficient cell lines, both HIF-alpha subunits are constitutively expressed, whereas re-introduction of a functional VHL gene restores the instability of HIF-1alpha and HIF-2alpha proteins under normoxic conditions. Moreover, immunohistochemical analyses of RCCs and hemangioblastomas demonstrate up-regulation of HIF-1alpha and HIF-2alpha in the tumor cells. The data presented here provide evidence for a role of the VHL protein in regulation of angiogenesis and erythropoiesis mediated by the HIF-1alpha and HIF-2alpha proteins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114720     DOI: 10.1038/sj.onc.1203938

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  118 in total

1.  Basal HIF-1α expression levels are not predictive for radiosensitivity of human cancer cell lines.

Authors:  D Schilling; C Bayer; K Emmerich; M Molls; P Vaupel; R M Huber; G Multhoff
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

2.  Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

Authors:  Raju R Raval; Kah Weng Lau; Maxine G B Tran; Heidi M Sowter; Stefano J Mandriota; Ji-Liang Li; Christopher W Pugh; Patrick H Maxwell; Adrian L Harris; Peter J Ratcliffe
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

3.  Targeted therapy for renal cell carcinoma: a new treatment paradigm.

Authors:  Thomas E Hutson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-07

Review 4.  The von Hippel-Lindau gene: turning discovery into therapy.

Authors:  Peter E Clark; Michael S Cookson
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

5.  Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis.

Authors:  Norihiko Takeda; Ellen L O'Dea; Andrew Doedens; Jung-whan Kim; Alexander Weidemann; Christian Stockmann; Masataka Asagiri; M Celeste Simon; Alexander Hoffmann; Randall S Johnson
Journal:  Genes Dev       Date:  2010-03-01       Impact factor: 11.361

6.  Erythropoietin inhibits HIF-1α expression via upregulation of PHD-2 transcription and translation in an in vitro model of hypoxia-ischemia.

Authors:  Rhonda Souvenir; Jerry J Flores; Robert P Ostrowski; Anatol Manaenko; Kamil Duris; Jiping Tang
Journal:  Transl Stroke Res       Date:  2013-11-27       Impact factor: 6.829

7.  Cancer Stem Cells under Hypoxia as a Chemoresistance Factor in Breast and Brain.

Authors:  Spencer W Crowder; Daniel A Balikov; Yu-Shik Hwang; Hak-Joon Sung
Journal:  Curr Pathobiol Rep       Date:  2014-03

8.  Progression of epididymal maldevelopment into hamartoma-like neoplasia in VHL disease.

Authors:  Gautam U Mehta; Sharon B Shively; Heng Duong; Maxine G B Tran; Travis J Moncrief; Jonathan H Smith; Jie Li; Nancy A Edwards; Russell R Lonser; Zhengping Zhuang; Marsha J Merrill; Mark Raffeld; Patrick H Maxwell; Edward H Oldfield; Alexander O Vortmeyer
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

9.  Human cancers converge at the HIF-2alpha oncogenic axis.

Authors:  Aleksandra Franovic; Chet E Holterman; Josianne Payette; Stephen Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-02       Impact factor: 11.205

10.  Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.

Authors:  C Alfaro; N Suarez; A Gonzalez; S Solano; L Erro; J Dubrot; A Palazon; S Hervas-Stubbs; A Gurpide; J M Lopez-Picazo; E Grande-Pulido; I Melero; J L Perez-Gracia
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.